** Shares of medtech firm Senseonics Holdings rise 12.7% to 44 cents
** Co and Ascensia Diabetes Care announce that the U.S. FDA has cleared its continuous glucose monitoring system (CGM) called Eversense 365, that can be worn for one year
** The CGM is for people with Type 1 and Type 2 diabetes aged 18 years and older
** The device has a sensor that can be worn for a year, compared to every 10-14 days with short-term CGM systems, co says
** Expects to initiate the US launch of Eversense 365 US in the fourth quarter of 2024
** Including session moves, stock down 23.9% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。